180 related articles for article (PubMed ID: 10582603)
1. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study.
Fornai F; Chen K; Giorgi FS; Gesi M; Alessandri MG; Shih JC
J Neurochem; 1999 Dec; 73(6):2434-40. PubMed ID: 10582603
[TBL] [Abstract][Full Text] [Related]
2. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Brannan T; Prikhojan A; MartÃnez-Tica J; Yahr MD
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):79-89. PubMed ID: 9620056
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
4. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
6. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Ilani T; Lamensdorf I; Finberg JP
Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
[TBL] [Abstract][Full Text] [Related]
7. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053
[TBL] [Abstract][Full Text] [Related]
8. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.
Azzaro AJ; King J; Kotzuk J; Schoepp DD; Frost J; Schochet S
J Neurochem; 1985 Sep; 45(3):949-56. PubMed ID: 3928811
[TBL] [Abstract][Full Text] [Related]
9. Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition.
Schoepp DD; Azzaro AJ
J Neurochem; 1981 Aug; 37(2):527-30. PubMed ID: 6790675
[TBL] [Abstract][Full Text] [Related]
10. Effect of selegiline on dopamine concentration in the striatum of a primate.
Kaseda S; Nomoto M; Iwata S
Brain Res; 1999 Jan; 815(1):44-50. PubMed ID: 9974121
[TBL] [Abstract][Full Text] [Related]
11. Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum.
Adachi K; Miwa H; Kusumoto H; Shimazu S; Kondo T
J Pharmacol Sci; 2006 Aug; 101(4):286-92. PubMed ID: 16891770
[TBL] [Abstract][Full Text] [Related]
12. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
[TBL] [Abstract][Full Text] [Related]
14. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Wachtel SR; Abercrombie ED
J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
Paterson IA; Juorio AV; Berry MD; Zhu MY
J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
[TBL] [Abstract][Full Text] [Related]
16. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
Sivam SP
Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
[TBL] [Abstract][Full Text] [Related]
17. Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa.
Fredriksson A; Palomo T; Archer T
Behav Pharmacol; 2000 Nov; 11(7-8):571-81. PubMed ID: 11198128
[TBL] [Abstract][Full Text] [Related]
18. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
Schoepp DD; Azzaro AJ
J Neurochem; 1981 Jun; 36(6):2025-31. PubMed ID: 6787175
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
20. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
